With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	1.12
Equity-to-Asset	0.34
Debt-to-Equity	0.25
Debt-to-EBITDA	0.23
Interest Coverage	69.78
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	13.36	Distress Grey Safe
Beneish M-Score	-2.58	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	24
	3-Year EBITDA Growth Rate	26.3
	3-Year EPS without NRI Growth Rate	26
	3-Year FCF Growth Rate	34.6
	3-Year Book Growth Rate	21.1
	Future 3-5Y EPS without NRI Growth Rate	18.44
	Future 3-5Y Total Revenue Growth Rate	18.85

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	60.52
	9-Day RSI	56.24
	14-Day RSI	54.61
	6-1 Month Momentum %	31.31
	12-1 Month Momentum %	59.88

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.82
	Quick Ratio	0.64
	Cash Ratio	0.18
	Days Inventory	284.46
	Days Sales Outstanding	87.92
	Days Payable	181.94

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.06
	Dividend Payout Ratio	0.38
	3-Year Dividend Growth Rate	18.1
	Forward Dividend Yield %	1.44
	5-Year Yield-on-Cost %	1.9
	3-Year Average Share Buyback Ratio	1.7
	Shareholder Yield %	1.83

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	84.6
	Operating Margin %	44.16
	Net Margin %	36.03
	FCF Margin %	30.14
	ROE %	92.29
	ROA %	30.18
	ROIC %	30.03
	ROC (Joel Greenblatt) %	138.16
	ROCE %	83.59
	Years of Profitability over Past 10-Year	10

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	47.62
	Forward PE Ratio	38.46
	PE Ratio without NRI	47.62
	Shiller PE Ratio	84.59
	Price-to-Owner-Earnings	44.98
	PEG Ratio	2.72
	PS Ratio	17.15
	PB Ratio	37.09
	Price-to-Tangible-Book	85.66
	Price-to-Free-Cash-Flow	57.03
	Price-to-Operating-Cash-Flow	36.62
	EV-to-EBIT	37.23
	EV-to-Forward-EBIT	31.07
	EV-to-EBITDA	34.2
	EV-to-Forward-EBITDA	28.45
	EV-to-Revenue	17.02
	EV-to-Forward-Revenue	13.77
	EV-to-FCF	55.19
	Price-to-Projected-FCF	5.25
	Price-to-DCF (Earnings Based)	2.22
	Price-to-DCF (FCF Based)	2.72
	Price-to-Median-PS-Value	2.09
	Price-to-Peter-Lynch-Fair-Value	2.93
	Price-to-Graham-Number	13.46
	Earnings Yield (Greenblatt) %	2.69
	FCF Yield %	1.77
	Forward Rate of Return (Yacktman) %	17.48

GF Value: kr689.34

OCSE:NOVO B

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with NOVO B. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.